当前位置:

安徽医科大学泌尿外科研究所

Institute   of   Urology,   Anhui   Medical   University

泌尿生殖系统疾病安徽省重点实验室

Anhui Province Key Laboratory of Genitourinary Diseases

安徽医科大学第一附属医院泌尿外科

Department of Urology, the First Affiliated Hospital of AHMU

孟佳林/Jialin Meng
    发布时间: 2020-11-06 16:22    

Name: Jialin Meng

Mobile Phone: +8618256921822 (China)

E-mail: mengjialin@ahmu.edu.cn

Name: Jialin Meng

Mobile Phone: +8618256921822 (China)

E-mail: mengjialin@ahmu.edu.cn

 

Education Background

…………………………………………………. ………………………………………………….

2010.09-2015.06 Anhui Medical University, Anhui, China

              Bachelor of Medicine

2016.07-2017.08 State Key Laboratory of Molecular Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

              Joint-training Program

2015.09-2018.06 First Affiliated Hospital of Anhui Medical University, Anhui, China

              Master of Medicine

2018.04-2020.07 School of Medicine, University of Rochester

              Postdoctoral Fellow

2018.09-now   First Affiliated Hospital of Anhui Medical University, Anhui, China

              Ph.D. Candidate

 

Publications                                                                             

First author [Total Impact Factor: 35.892]

----------------------------------------------------------------------------------------------------------------------

1.        Meng J, Zhou Y, Lu X, Bian Z, Chen Y, Zhou J, Zhang L, Hao Z, Zhang M, Liang C. Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy. Molecular Oncology, 2020.12. doi:10.1002/1878-0261.12887 ([Article], 第一作者, IF=6.547, 中科院2, JCR 1).

2.        Meng J, Lu X, Zhou Y, Zhang M, Gao L, Gao S, Yan F, Liang C. Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel-like factors in prostate cancer. Journal of Cellular and Molecular Medicine. 2020 Apr 13;24(10):5797-810. doi: 10.1111/jcmm.15242 ([Article], 第一作者, IF=4.486, 中科院2, JCR 2 ).

3.        Meng J, Lu X, Zhou Y, Zhang M, Ge Y, Zhou J, Hao Z, Gao S, Yan F, Liang C. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. [J] Molecular Therapy Oncolytics, 20:410-421. doi: 10.1016/j.omto.2021.02.001 ([Article], 第一作者, IF=4.115, 中科院2, JCR 1 ).

4.        Meng J, Liu Y, Guan S, Fan S, Zhou J, Zhang M, & Liang C. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. [J] Cancer medicine. 2019 Sep;8(11):5202-13. doi: 10.1002/cam4.2433 ([Article], 第一作者, IF=3.491, 中科院3, JCR 2 )

5.        Meng J, Wang S, Zhang M, Fan S, Zhang L, Liang C. TP73 G4C14-A4T14 Polymorphism and Cancer Susceptibility: Evidence from 36 case-control studies. doi: 10.1042/BSR20181452 [J] Bioscience Reports. 2018 Dec 21;38(6): BSR20181452. ([Article], 第一作者, IF=2.942, 中科院4, JCR 3 )

6.        Meng J, Gao L, Zhang M, Gao S, Fan S, Liang C. Systematic investigation of the prognostic value of cell division cycle-associated proteins for clear cell renal cell carcinoma patients. [J] Biomarkers in Medicine. 2020 Jan. doi: 10.2217/bmm-2019-0498. ([Article], 第一作者, IF=2.479, 中科院4, JCR 2 )

7.        Meng J, Liu Y, Guan SY, Ma HY, Zhang XY, Fan S, Hu HQ, Zhang M, Liang CZ. Age, height, BMI and FBG, the predicting biomarkers of prostate volume among aging benign prostatic hyperplasia: evidence from 5285 patients. [J] International Journal of Clinical Practice.  2019;73: e13438. doi: 10.1111/ijcp.13438 ([Article], 第一作者, IF=2.444, 中科院3, JCR 1 )

8.        Meng J, Wang S, Shen X, Bai Z, Niu Q, Ma D, Xu Y, Liang C. Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis.[J] Pathology Research and Practice. 2018 Dec;214(12):1966-1973. doi: 10.1016/j.prp.2018.09.011. ([Article], 第一作者, IF=2.050, 中科院4, JCR 3 )

9.        Meng J, Li W, Zhang M, Hao Z, Fan S, Zhang L, Liang C. An update meta-analysis and systematic review of TAP polymorphisms as potential biomarkers for judging cancer risk. [J] Pathology Research and Practice. 2018 Oct;214(10):1556-1563. doi: 10.1016/j.prp.2018.07.018. ([Article], 第一作者, IF=2.050, 中科院4, JCR 3 )

10.     Meng J, Xu Y, Li A, Fan S, Shen X, Ma D, Zhang L, Hao Z, Zhang X, Liang C. Clinical Features of 167 Inpatients with Autosomal Dominant Polycystic Kidney Disease at a Single Center in China. [J] Medical Science Monitor. 2018 Sep 16; 24: 6498-6505. doi: 10.12659/MSM.910127. ([Article], 第一作者, IF=1.918, 中科院4, JCR 3)

11.     Meng J, Xu Y, Shen X, Liang C. A novel frameshift PKD1 mutation in a Chinese patient with autosomal dominant polycystic kidney disease and azoospermia: A case report. [J] Experimental and therapeutic Medicine. 2018, 17: 507-511. doi: 10.3892/etm.2018.6946 ([Article], 第一作者, IF=1.785, 中科院4, JCR 4)

12.     Meng J, Fan X, Zhang M, Hao Z, Liang C. Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review. [J] BMC Medical Genetics. 2018 Oct 19;19(1):189. doi: 10.1186/s12881-018-0704-8. ([Article], 第一作者, IF=1.585, 中科院4, JCR 4)

 

Co-first, co-corresponding author [Total Impact Factor: 36.039]

----------------------------------------------------------------------------------------------------------------------

1.        Gao L#, Meng J.# (co-first author), Zhang Y, Gu J, Han Z, Wang X, Gao SL. Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer. Genomics, 112(6):4980-4992. ([Article], 共同一作, 排名第2, IF=6.205, 中科院2, JCR 1)

2.        Lu, X. #, Zhou, Y. #, Meng J.# (co-first author),  Jiang, L., Gao, J., Cheng, Y., Yan, H., Wang, Y., Zhang, B., Li, X. and Yan, F., RNA processing genes characterize RNA splicing and further stratify colorectal cancer. Cell Proliferation, p.e12861. ([Article], 共同一作, 排名第3, IF=5.753, 中科院2, JCR 1)

3.        Lu X.#, Zhou Y.#, Meng J.# (co-first author) et al. Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoactivation, and favourable prognosis. [J] Clinical Epigenetics, 12, 23 (2020). doi:10.1186/s13148-020-0822-y ([Article], 共同一作, 排名第3, IF=5.028, 中科院2, JCR 1)

4.        Zhou Y.#, Lu X.#, Meng J.# (co-first author) et al. Qualitative transcriptional signature for the pathological diagnosis of pancreatic cancer." Frontiers in Molecular Biosciences (2020): ([Article], 共同一作, 排名第3, IF=4.462, 中科院3, JCR 2)

5.        Xia H, Chen Y, Meng J* (Co-corresponding author) Liang C*. Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects. [J] Artificial cells, nanomedicine, and biotechnology. 2019 Dec 4;47(1):3138-52. doi: 10.1080/21691401.2019.1646750 ([Article], 共同通讯, 排名第2, IF=4.188, 中科院3, JCR 2)

6.        Gao L, Meng J*, Zhang M, Fan S, Gao S, Wang X, Liang C. Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer. DNA and Cell Biology. 2020 Apr 29. doi: 10.1089/dna.2019.5224 ([Article], 共同一作, 排名第2, IF=3.191, 中科院3, JCR 2)

7.        Bian Z#, Meng J# (co-first author), Niu Q, Jin X, Wang J, Feng X, Che H, Zhou J, Zhang L, Zhang M, Liang C. Prognostic Role of Prothrombin Time Activity, Prothrombin Time, Albumin/Globulin Ratio, Platelets, Sex, and Fibrinogen in Predicting Recurrence-Free Survival Time of Renal Cancer. Cancer Management and Research. 2020;12:8481-8490 doi:10.2147/CMAR.S264856 ([Article], 共同一作, 排名第2, IF=2.886, 中科院3, JCR 2)

8.        Fan S#, Meng J# (co-first author), Zhang L, Zhang X, Liang C. CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. [J] Pathology Research and Practice. 2018 Nov 13. pii: S0344-0338(18)31242-1. doi: 10.1016/j.prp.2018.11.009. ([Article], 第一作者, IF=2.050, 中科院4, JCR 3 )

 


研究团队